Billion

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noreferrer noopener" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div> 
<p class="has-drop-cap">Pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced Thursday its decision to <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moves-forward-with-once-daily-weight-loss-drug-2024-07-11/" target="_blank" aria-label="move forward (opens in a new tab)" rel="noreferrer noopener nofollow" class="deco-link">move forward</a> with the development of a once-daily version of its weight loss pill, danuglipron, sparking a positive response from investors. The company’s stock rose 1.90% to $28.89 in early trading today.</p> 
<h3 id="pfizer-s-weight-loss-pill-development">Pfizer’s Weight Loss Pill Development</h3> 
<p>Pfizer’s decision to continue developing danuglipron comes after “encouraging” data from an ongoing early-stage trial. The company identified a formulation with the most favorable safety profile and bodily reactions, paving the way for additional early-stage trials in the second half of 2024. Results from these trials are expected in the first quarter of 2025.</p> 
<p>Dr. Mikael Dolsten, Pfizer’s outgoing Chief Scientific Officer, expressed confidence in the drug’s potential, stating that the once-daily formulation could be competitive in the oral GLP-1 agonist space. This class of drugs, which includes Novo Nordisk’s popular Wegovy and Ozempic, has seen soaring demand for weight loss and diabetes treatment.</p> 
<p>The advancement of danuglipron represents a significant turnaround for Pfizer, which discontinued the twice-daily version of the drug in December due to tolerability issues. <br><br>Notably, no liver safety issues were observed in patients receiving the once-daily formulations, addressing a key concern that had previously hindered the company’s progress in this therapeutic area.</p> 
<div class="cta-referral"> 
 <img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async"> 
 <div class="cta-referral__text"> 
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noreferrer noopener nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p> 
 </div> 
</div> 
<h3 id="pfizer-s-moment-in-the-glp-1-market">Pfizer’s Moment in the GLP-1 Market</h3> 
<p>This development keeps Pfizer in contention for a share of the projected $100 billion GLP-1 market, maintaining competitive pressure on market leaders Novo Nordisk and Eli Lilly (NYSE: LLY). <br><br>It also signals Pfizer’s strategy to focus on internal development rather than late-stage acquisitions, though the company may still consider licensing deals or acquiring earlier-stage weight loss drugs.</p> 
<p>The news has implications for Pfizer’s financial outlook and stock performance. While the company’s stock is up 3.39% year-to-date, it has underperformed <a href="https://tokenist.com/investing/spx-vs-spy/" rel="dofollow" class="deco-link">the S&amp;P 500’s 18.14% gain</a>. <br><br>Pfizer’s market capitalization stands at $163.702 billion, with a <a href="https://tokenist.com/investing/p-e-ratio/" rel="dofollow" class="deco-link">forward P/E ratio</a> of 12.30 and a dividend yield of 5.43%. However, the company reported negative <a href="https://tokenist.com/investing/how-to-value-a-stock/" class="deco-link">earnings per share</a> of $0.05 over the trailing twelve months, reflecting recent challenges. </p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe> 
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em>s</p> 
<h3 id="br"><br></h3> 
<p>The post <a rel="nofollow" href="https://tokenist.com/wall-street-weighs-in-as-pfizer-targets-100-billion-weight-loss-market/">Wall Street Weighs in as Pfizer Targets $100 Billion Weight Loss Market</a> appeared first on <a rel="nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Wall Street Weighs in as Pfizer Targets $100 Billion Weight Loss Market

Table of Contents

Tokenist

Other articles published on Jul 11, 2024

Qubetics Whitelist Makes Headway as Solana and Avalanche Fail to Counter Market Shifts

Analyst Predicts Solana’s Strong Performance

Shiba Inu Team Gives 4 Reasons Why SHIB ETF Is Imminent

U.S. inflation falls to 3%, lowest level since 2021

TON Application Chain And Polygon Labs Partner For New TON L2 Launch

Diljit Dosanjh Wows Fans at Crypto Arena in Los Angeles

Join our free newsletter for daily crypto updates!